Lung Cancer Research

Category: Cancer

Get research like this delivered to your inbox — free

Rivvet may earn a referral fee if you book through this link.

Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.

The Lancet. Oncology · Apr 1, 2026

What's New: Fulzerasib plus cetuximab achieved a 69% confirmed objective response rate as first-line therapy in KRASG12C-mutated non-small-cell lung cancer.